Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) reported unaudited financial results for the third quarter ended Dec. 31, 2025, highlighting continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder. The company ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities.
Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio and upcoming clinical data milestones in 2026. Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity.
HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company has an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit www.helus.com. The full press release is available at https://ibn.fm/VigPf.
